248 related articles for article (PubMed ID: 37041154)
21. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
22. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
[TBL] [Abstract][Full Text] [Related]
24. STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland.
Maia CJ; Socorro S; Schmitt F; Santos CR
Endocrine; 2008; 34(1-3):108-16. PubMed ID: 18958632
[TBL] [Abstract][Full Text] [Related]
25. The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.
Herrmann VL; Wieland DE; Legler DF; Wittmann V; Groettrup M
Prostate; 2016 Apr; 76(5):456-68. PubMed ID: 26715028
[TBL] [Abstract][Full Text] [Related]
26. Fully human antibody V
Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386
[TBL] [Abstract][Full Text] [Related]
27. Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis by aiding progression of epithelial-to-mesenchymal transition.
Jiao Z; Huang L; Sun J; Xie J; Wang T; Yin X; Zhang H; Chen J
Histochem Cell Biol; 2020 Aug; 154(2):215-230. PubMed ID: 32382787
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of STEAP1 extracellular vesicles in prostate cancer.
Khanna K; Salmond N; Lynn KS; Leong HS; Williams KC
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):802-811. PubMed ID: 33589770
[TBL] [Abstract][Full Text] [Related]
30. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
Kloss CC; Lee J; Zhang A; Chen F; Melenhorst JJ; Lacey SF; Maus MV; Fraietta JA; Zhao Y; June CH
Mol Ther; 2018 Jul; 26(7):1855-1866. PubMed ID: 29807781
[TBL] [Abstract][Full Text] [Related]
31. STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Rocha SM; Nascimento D; Coelho RS; Cardoso AM; Passarinha LA; Socorro S; Maia CJ
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047621
[TBL] [Abstract][Full Text] [Related]
32. STEAP1 Inhibits Breast Cancer Metastasis and Is Associated With Epithelial-Mesenchymal Transition Procession.
Xie J; Yang Y; Sun J; Jiao Z; Zhang H; Chen J
Clin Breast Cancer; 2019 Feb; 19(1):e195-e207. PubMed ID: 30253922
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and Biodistribution of a [
O'Donoghue JA; Danila DC; Pandit-Taskar N; Beylergil V; Cheal SM; Fleming SE; Fox JJ; Ruan S; Zanzonico PB; Ragupathi G; Lyashchenko SK; Williams SP; Scher HI; Fine BM; Humm JL; Larson SM; Morris MJ; Carrasquillo JA
Mol Pharm; 2019 Jul; 16(7):3083-3090. PubMed ID: 31117485
[TBL] [Abstract][Full Text] [Related]
34. Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells
Yamasaki S; Shimizu K; Fujii SI
Front Immunol; 2024; 15():1345037. PubMed ID: 38361934
[TBL] [Abstract][Full Text] [Related]
35. STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.
Rocha SM; Nascimento D; Cardoso AM; Passarinha L; Socorro S; Maia CJ
Mol Med Rep; 2023 Feb; 27(2):. PubMed ID: 36660947
[TBL] [Abstract][Full Text] [Related]
36. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
37. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.
Murad JP; Tilakawardane D; Park AK; Lopez LS; Young CA; Gibson J; Yamaguchi Y; Lee HJ; Kennewick KT; Gittins BJ; Chang WC; Tran CP; Martinez C; Wu AM; Reiter RE; Dorff TB; Forman SJ; Priceman SJ
Mol Ther; 2021 Jul; 29(7):2335-2349. PubMed ID: 33647456
[TBL] [Abstract][Full Text] [Related]
38. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
